Personalized Vaccine for Patients With Recurrent Malignant Glioma
Personalized Vaccine for Patients With Recurrent Malignant Glioma: a Single-arm, Single-center, Open-labeled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Qingtang Lin, M.D., Ph.D.
- Phone Number: 2683 8610-83198114
- Email: linqingtang@xwhosp.org
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100054
- Recruiting
- Xuanwu Hospital, Capital Medical University
-
Contact:
- Ye Cheng, M.D.
- Phone Number: 2683 8610-83188114
- Email: chengye@xwhosp.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18-70;
- signed inform consent;
- patients with recurrent malignant glioma; have received surgery, radiotherapy, chemotherapy;
- patients' tumor tissue should have a high mutation load(>10 TMB); be genetically unstable; at least have 10 neoantigens;
- should be able to provide tumor tissue and peripheral blood for sequencing and flow cytometry analysis;
- at least three months post last operation; one month after the completion of the last anti-drug therapy or radiotherapy;
- have not received any immune therapy;
- at least have one measurable lesion;
- KPS >60;
- estimated survival > 3 months
- patients should have adequate organ and bone marrow function;
Exclusion Criteria:
- female patient is breastfeeding or pregnant;
- known history of allergy to peptides or other stimulating factors (i.e. GM-CSF);
- known history of Graft-Versus-Host Disease (GVHD);
- participation in gene therapy;
- other malignancy;
- systemic disease: i.e., severe infection; HIV;
- other conditions upon investigator's judgement;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: personalized vaccine
patients with recurrent malignant gliomas enrolled into this arm will receive the personalized vaccine through sub-cutaneous.
|
Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; patients would be vaccinated on day 1, 4, 8 ,15, 22 and then on week 12, 20.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
incidences of advent events and severe advent events
Time Frame: from initiation of study treatment to 28 weeks post-vaccination
|
would be monitored and measured according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.X.)
|
from initiation of study treatment to 28 weeks post-vaccination
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
object response rate (ORR) according to iRANO criteria
Time Frame: from initiation of study treatment to 24 weeks post-vaccination (last shot)
|
ORR including complete response (CR) and partial response (PR) would be assessed and measured based on the conditions proposed by iRANO criteria
|
from initiation of study treatment to 24 weeks post-vaccination (last shot)
|
|
progression free survival (PFS)
Time Frame: up to 48 weeks post-vaccination(last shot)
|
time interval (measured in weeks) between initiation of study treatment to progression of disease
|
up to 48 weeks post-vaccination(last shot)
|
|
overall survival (OS)
Time Frame: up to 48 weeks post-vaccination(last shot)
|
time interval (measured in weeks) from initiation of study treatment to the death of patients
|
up to 48 weeks post-vaccination(last shot)
|
|
immune response based on the criteria encoded by GRT-C903 and GRT-R904
Time Frame: Baseline to end of treatment (up to approximately 12 months)
|
humoral and cellular immune responses including generation of specific antibodies, inflammatory factors, immune cells, will be measured as proposed by GRT-C903 and GRT-R904
|
Baseline to end of treatment (up to approximately 12 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2019-127
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.